HomeClinical TopicsFDA approves first epoetin alfa biosimilar

FDA approves first epoetin alfa biosimilar

Author(s):

On May 15, the U.S. Food and Drug Administration (FDA) approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection.

Read more via FDA.gov.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

NP taking pregnant woman's blood pressure

AHA: It’s Safe to Treat High Blood Pressure During Pregnancy

High blood pressure during pregnancy can present significant risks to mother and child, but practitioners have sometimes be hesitant to prescribe blood pressure medication...